Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

Next Previous
Trial Profile

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TNACITY
  • Sponsors Abraxis BioScience; Celgene Corporation

Most Recent Events

  • 16 Dec 2021 This trial has been discontinued in Austria, Germany, Portugal, UK and Greece. Whereas, completed in France, Italy and Spain according to European Clinical Trials Database record.
  • 06 Jun 2018 Results from phase II portion of the study published in the Annals of Oncology.
  • 30 Mar 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top